Literature DB >> 11158762

Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.

A M Sugar1, X P Liu.   

Abstract

We evaluated the efficacy of voriconazole, a new broad-spectrum triazole antifungal compound, in the treatment of murine pulmonary blastomycosis. Since mice metabolize voriconazole rapidly, we took advantage of our previous observation that administration of grapefruit juice to mice resulted in suitable serum voriconazole concentrations so that treatment studies with mice could be done (A. M. Sugar and X.-P. Liu, Med. Mycol. 38:209-121, 2000). Our results show that voriconazole prolonged survival in a dose-dependent fashion and that the fungal burden in the lungs was decreased by voriconazole administered at 40 mg/kg of body weight/day. Voriconazole should be studied in humans with blastomycosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158762      PMCID: PMC90334          DOI: 10.1128/AAC.45.2.601-604.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  The interaction effect of grapefruit juice is maximal after the first glass.

Authors:  J U Lundahl; C G Regårdh; B Edgar; G Johnsson
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

2.  Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice.

Authors:  C A Lyman; A M Sugar; R D Diamond
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

3.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

Authors:  A M Sugar; X P Liu
Journal:  Med Mycol       Date:  2000-06       Impact factor: 4.076

4.  Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine.

Authors:  W K Chan; L T Nguyen; V P Miller; R Z Harris
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

5.  In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.

Authors:  F Marco; M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

7.  Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.

Authors:  M A Ghannoum; I Okogbule-Wonodi; N Bhat; H Sanati
Journal:  J Chemother       Date:  1999-02       Impact factor: 1.714

8.  Efficacy of itraconazole in blastomycosis in a murine model and comparison with ketoconazole.

Authors:  E G Arathoon; E Brummer; D A Stevens
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

9.  Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.

Authors:  M Cuenca-Estrella; J L Rodríguez-Tudela; E Mellado; J V Martínez-Suárez; A Monzón
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

10.  Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans.

Authors:  D G Bailey; J H Kreeft; C Munoz; D J Freeman; J R Bend
Journal:  Clin Pharmacol Ther       Date:  1998-09       Impact factor: 6.875

View more
  21 in total

1.  Combined therapies in a murine model of blastoschizomycosis.

Authors:  Carolina Serena; M Mar Rodríguez; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

2.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

4.  Pulmonary blastomycosis masquerading as metastatic disease in the lung: a case report.

Authors:  Bobbak Vahid; Bernadette Wildemore; Christopher Nguyen; Niki Sistrun; Paul E Marik
Journal:  MedGenMed       Date:  2006-01-31

5.  Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.

Authors:  Enrique Calvo; F Javier Pastor; Emilio Mayayo; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

6.  Experimental murine scedosporiosis: histopathology and azole treatment.

Authors:  M Mar Rodríguez; F Javier Pastor; Valentina Salas; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

7.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

8.  Antifungal therapy of murine Aspergillus terreus infection.

Authors:  John R Graybill; Steve Hernandez; Rosie Bocanegra; Laura K Najvar
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.